INVESTIGATION OF INTRODUCTION OF NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS IN OUR HOSPITAL

Background and Aims: Nintedanib, an oral tyrosine kinase inhibitor, has been shown to slow down the progression of idiopathic pulmonary fibrosis (IPF) in two randomised placebo-controlled trials by reducing the annual decline in forced vital capacity (FVC). However, data on the efficacy and safety of nintedanib for idiopathic pulmonary fibrosis is not sufficient. Methods: We investigated, retrospectively, the effects and side effects, and so on, of nintedanib in 6 patients with IPF who were interventionally treated with nintedanib from October 2015 to May 2018. Results: There are 6 subjects, male/female = 4 cases 2 cases, average age 70.3 years old, GAP index I/II/III/unknown = 0 cases/4 cases/1 case/1 case, %FVC 57.6 12.9%, %DLCO 33.5 11.6%, and KL-6 1399 948 U/mL. Four cases were discontinued, the reason for stopping was 2 cases of anorexia/1 case of liver function disorder, 1 case of blood sputum, and restarted in 2 cases. In addition, there was one case in which we continued oral administration after weight loss. One case was seen in which Nintedanib’s involvement died of onset of kidney failure that cannot be denied. 3 cases improved %FVC, 4 cases showed a decrease in KL-6. Conclusion: There is a possibility that improvement of %FVC, KL-6 decrease can be expected by Nintedanib in some special cases which is a part of many IPF patients. However, when using nintedanib, adequate caution is required for the occurrence of adverse events. We will analyze and report in more detail at the 23rd Congress of the APSR.